GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » FDC Ltd (NSE:FDC) » Definitions » YoY EBITDA Growth

FDC (NSE:FDC) YoY EBITDA Growth : 35.10% (As of Mar. 2024)


View and export this data going back to 1997. Start your Free Trial

What is FDC YoY EBITDA Growth?

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. FDC's YoY EBITDA Growth for the quarter that ended in Mar. 2024 was 35.10%.

FDC's EBITDA per Share for the three months ended in Mar. 2024 was ₹4.55.

FDC YoY EBITDA Growth Historical Data

The historical data trend for FDC's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

FDC YoY EBITDA Growth Chart

FDC Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
YoY EBITDA Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only 34.85 20.27 -22.61 -7.30 48.23

FDC Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 101.07 57.06 30.88 63.63 35.10

FDC YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

FDC's YoY EBITDA Growth for the fiscal year that ended in Mar. 2024 is calculated as:

YoY EBITDA Growth (A: Mar. 2024 )
=(EBITDA per Share (A: Mar. 2024 )-EBITDA per Share (A: Mar. 2023 ))/ | EBITDA per Share (A: Mar. 2023 ) |
=(26.795-18.077)/ | 18.077 |
=48.23 %

FDC's YoY EBITDA Growth for the quarter that ended in Mar. 2024 is calculated as:

YoY EBITDA Growth (Q: Mar. 2024 )
=(EBITDA per Share (Q: Mar. 2024 )-EBITDA per Share (Q: Mar. 2023 )) / | EBITDA per Share (Q: Mar. 2023 )) |
=(4.553-3.37)/ | 3.37 |
=35.10 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

FDC YoY EBITDA Growth Related Terms

Thank you for viewing the detailed overview of FDC's YoY EBITDA Growth provided by GuruFocus.com. Please click on the following links to see related term pages.

FDC (NSE:FDC) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » FDC Ltd (NSE:FDC) » Definitions » YoY EBITDA Growth
Comparable Companies
BOM:530019 BOM:524558 NSE:STAR BOM:532872 BOM:524348 BOM:543322 BOM:524742 BOM:532482 BOM:543748 BOM:500126 ZTS XTER:MRK TSE:4502 LSE:HLN NSE:SUNPHARMA TSE:4523 TSE:4507 SZSE:000538 XSWX:SDZ HKSE:03692
Traded in Other Exchanges
531599:India
Address
C-3 Skyvistas, Near Versova Police Station, D.N. Nagar, Andheri (West), Mumbai, MH, IND, 400053
Website
https://www.fdcindia.com
FDC Ltd is an Indian-based pharmaceutical company with USFDA and UK-MHRA-approved API and formulations manufacturing facilities. It has its presence in numerous therapeutic segments: Anti-infectives, Gastro-Intestinal, Vitamins/Minerals/Nutrients, Ophthalmology/Otologicals, Cardiac, Dermatology, Respiratory, Gynaecology, and Others. The company's brands include Zifi, Electral, Enerzal, Vitcofol, Pyrimon, Zocon, Zoxan, Zathrin, Zipod, Zefu, Cotaryl, and Mycoderm. The majority of the revenue is generated domestically.